Edison Pharmaceuticals has started a phase 2B study, which will investigate new treatments for Friedreich's ataxia. The trial is entitled Safety and Efficacy Study of EPI-743 on Visual Function in Patients with Friedreich's Ataxia. It is ...
Tags: Edison Pharmaceuticals, disease severity, neuromuscular function